

Bernard Ce Khoo

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4418217/publications.pdf>

Version: 2024-02-01

54
papers

2,176
citations

304602

22
h-index

223716

46
g-index

56
all docs

56
docs citations

56
times ranked

3530
citing authors

#	ARTICLE	IF	CITATIONS
1	Preserved C-peptide in survivors of COVID-19: Post hoc analysis. <i>Diabetes, Obesity and Metabolism</i> , 2022, 24, 570-574.	2.2	8
2	A Comparison of the Blood Glucose, Growth Hormone, and Cortisol Responses to Two Doses of Insulin (0.15%U/kg vs. 0.10%U/kg) in the Insulin Tolerance Test: A Single-Centre Audit of 174 Cases. <i>International Journal of Endocrinology</i> , 2022, 2022, 1-8.	0.6	1
3	Steps to redressing an imbalance: GLP-1 analogues for obesity in east Asia. <i>Lancet Diabetes and Endocrinology</i> , the, 2022, , .	5.5	0
4	Ockham's Razor for a Retinal Lesion and Acromegaly and Breaking the Vicious Circle. <i>Journal of the Endocrine Society</i> , 2022, 6, .	0.1	2
5	Thyroid Function Before, During, and After COVID-19. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2021, 106, e803-e811.	1.8	143
6	Safety and efficacy of an extended-release peptide YY analogue for obesity: A randomized, placebo-controlled, phase 1 trial. <i>Diabetes, Obesity and Metabolism</i> , 2021, 23, 1471-1483.	2.2	9
7	Misleading ⁶⁸ GALLIUM-dotatate PET scan in a patient with a history of a pheochromocytoma: Unsuspected uptake in papillary thyroid carcinoma metastases. <i>Journal of Neuroendocrinology</i> , 2021, 33, e12964.	1.2	1
8	Differential effects of bile acids on the postprandial secretion of gut hormones: a randomized crossover study. <i>American Journal of Physiology - Endocrinology and Metabolism</i> , 2021, 320, E671-E679.	1.8	8
9	Normal Adrenal and Thyroid Function in Patients Who Survive COVID-19 Infection. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2021, 106, 2208-2220.	1.8	50
10	Tirzepatide and the new era of twincretins for diabetes. <i>Lancet, The</i> , 2021, 398, 95-97.	6.3	4
11	Metastatic Medullary Thyroid Cancer: The Role of ⁶⁸ Gallium-DOTA-Somatostatin Analogue PET/CT and Peptide Receptor Radionuclide Therapy. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2021, 106, e4903-e4916.	1.8	15
12	Surpassing insulin glargine in type 2 diabetes with tirzepatide. <i>Lancet, The</i> , 2021, 398, 1779-1781.	6.3	3
13	Roux-en-Y Gastric Bypass Increases Glycemic Variability and Time in Hypoglycemia in Patients With Obesity and Prediabetes or Type 2 Diabetes: A Prospective Cohort Study. <i>Diabetes Care</i> , 2021, 44, 614-617.	4.3	9
14	Understanding the treatment algorithm of patients with metastatic pancreatic neuroendocrine neoplasms: A single-institution retrospective analysis comparing outcomes of chemotherapy, molecular targeted therapy and peptide receptor radionuclide therapy in 255 patients. <i>Neuroendocrinology</i> , 2020, 111, 863-875.	1.2	3
15	Cortisol concentrations and mortality from COVID-19 " Authors' reply. <i>Lancet Diabetes and Endocrinology</i> , the, 2020, 8, 809-810.	5.5	6
16	Association between high serum total cortisol concentrations and mortality from COVID-19. <i>Lancet Diabetes and Endocrinology</i> , the, 2020, 8, 659-660.	5.5	193
17	Proglucagon peptide secretion profiles in type 2 diabetes before and after bariatric surgery: 1-year prospective study. <i>BMJ Open Diabetes Research and Care</i> , 2020, 8, e001076.	1.2	18
18	Combination gut hormones: prospects and questions for the future of obesity and diabetes therapy. <i>Journal of Endocrinology</i> , 2020, 246, R65-R74.	1.2	18

#	ARTICLE	IF	CITATIONS
19	Peptide Receptor Radionuclide Therapy as a Novel Treatment for Metastatic and Invasive Pheochromocytoma and Paraganglioma. <i>Neuroendocrinology</i> , 2019, 109, 287-298.	1.2	48
20	Once-daily, modified-release hydrocortisone in patients with adrenal insufficiency. <i>Lancet Diabetes and Endocrinology</i> , 2018, 6, 269.	5.5	4
21	Assessment and Management of Anti-Insulin Autoantibodies in Varying Presentations of Insulin Autoimmune Syndrome. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2018, 103, 3845-3855.	1.8	24
22	Peptide Receptor Radionuclide Treatment and (131)I-MIBG in the management of patients with metastatic/progressive pheochromocytomas and paragangliomas. <i>Journal of Surgical Oncology</i> , 2017, 115, 425-434.	0.8	64
23	Renin-Angiotensin System Blockade Improves Cardiac Indices in Acromegaly Patients. <i>Experimental and Clinical Endocrinology and Diabetes</i> , 2017, 125, 365-367.	0.6	7
24	Delivery is key: lessons learnt from developing splice-switching antisense therapies. <i>EMBO Molecular Medicine</i> , 2017, 9, 545-557.	3.3	119
25	Redefining the stress cortisol response to surgery. <i>Clinical Endocrinology</i> , 2017, 87, 451-458.	1.2	46
26	Cell-type-specific modulation of innate immune signalling by vitamin D in human mononuclear phagocytes. <i>Immunology</i> , 2017, 150, 55-63.	2.0	23
27	Real-life experience of tolvaptan use in the treatment of severe hyponatraemia due to syndrome of inappropriate antidiuretic hormone secretion. <i>Clinical Endocrinology</i> , 2016, 84, 620-626.	1.2	46
28	Pheochromocytomas and Paragangliomas: A difference in disease behaviour and clinical outcomes. <i>Journal of Surgical Oncology</i> , 2015, 112, 486-491.	0.8	15
29	Genetic therapies to lower cholesterol. <i>Vascular Pharmacology</i> , 2015, 64, 11-15.	1.0	5
30	Landscape of Familial Isolated and Young-Onset Pituitary Adenomas: Prospective Diagnosis in AIP Mutation Carriers. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2015, 100, E1242-E1254.	1.8	144
31	Distinct patterns of heparan sulphate in pancreatic islets suggest novel roles in paracrine islet regulation. <i>Molecular and Cellular Endocrinology</i> , 2015, 399, 296-310.	1.6	17
32	Splicing modulation therapy in the treatment of genetic diseases. <i>The Application of Clinical Genetics</i> , 2014, 7, 245.	1.4	33
33	Inflammatory myofibroblastic tumour arising in the adrenal gland: a case report. <i>Journal of Medical Case Reports</i> , 2014, 8, 411.	0.4	4
34	Multicentre study of investigation and management of inpatient hyponatraemia in the UK. <i>Postgraduate Medical Journal</i> , 2014, 90, 694-698.	0.9	25
35	Regulation of CYP27B1 and CYP24A1 hydroxylases limits cell-autonomous activation of vitamin D in dendritic cells. <i>European Journal of Immunology</i> , 2014, 44, 1781-1790.	1.6	41
36	Development of Therapeutic Splice-Switching Oligonucleotides. <i>Human Gene Therapy</i> , 2014, 25, 587-598.	1.4	59

#	ARTICLE	IF	CITATIONS
37	Radiology reporting of adrenal incidentalomas " who requires further testing?. Clinical Medicine, 2014, 14, 16-21.	0.8	6
38	Multiple tandem splicing silencer elements suppress aberrant splicing within the long exon 26 of the human Apolipoprotein B gene. BMC Molecular Biology, 2013, 14, 5.	3.0	1
39	Exon Skipping of Hepatic APOB Pre-mRNA With Splice-switching Oligonucleotides Reduces LDL Cholesterol In Vivo. Molecular Therapy, 2013, 21, 602-609.	3.7	26
40	Pancreatic Adenocarcinoma in a Patient With Multiple Endocrine Neoplasia 1 Syndrome. Pancreas, 2013, 42, 725-726.	0.5	4
41	Antisense-Mediated Exon-Skipping to Induce Gene Knockdown. Methods in Molecular Biology, 2012, 867, 289-305.	0.4	7
42	"Running on empty"™. European Journal of Nuclear Medicine and Molecular Imaging, 2010, 37, 1439-1440.	3.3	5
43	Characterization of aryl hydrocarbon receptor interacting protein (AIP) mutations in familial isolated pituitary adenoma families. Human Mutation, 2010, 31, 950-960.	1.1	154
44	Repair of Aberrant Splicing in Growth Hormone Receptor by Antisense Oligonucleotides Targeting the Splice Sites of a Pseudoexon. Journal of Clinical Endocrinology and Metabolism, 2010, 95, 3542-3546.	1.8	10
45	Malignant Somatostatinoma Presenting with Diabetic Ketoacidosis and Inhibitory Syndrome: Pathophysiologic Considerations. Endocrine Practice, 2010, 16, 835-837.	1.1	8
46	Contrasting clinical manifestations of SDHB and VHL associated chromaffin tumours. Endocrine-Related Cancer, 2009, 16, 515-525.	1.6	35
47	MELAS syndrome, diabetes and thyroid disease: the role of mitochondrial oxidative stress. Clinical Endocrinology, 2009, 70, 340-341.	1.2	12
48	Splicing therapeutics in SMN2 and APOB. Current Opinion in Molecular Therapeutics, 2009, 11, 108-115.	2.8	24
49	Clinical manifestations of familial paraganglioma and pheochromocytomas in succinate dehydrogenase B (SDHB) gene mutation carriers. Clinical Endocrinology, 2008, 69, 587-596.	1.2	81
50	Pre-Spliceosomal Binding of U1 Small Nuclear Ribonucleoprotein (RNP) and Heterogenous Nuclear RNP E1 Is Associated with Suppression of a Growth Hormone Receptor Pseudoexon. Molecular Endocrinology, 2007, 21, 2529-2540.	3.7	36
51	Antisense oligonucleotide-induced alternative splicing of the APOB mRNA generates a novel isoform of APOB. BMC Molecular Biology, 2007, 8, 3.	3.0	44
52	Mutations in MRAP, encoding a new interacting partner of the ACTH receptor, cause familial glucocorticoid deficiency type 2. Nature Genetics, 2005, 37, 166-170.	9.4	388
53	Somatostatin Infusion Lowers Plasma Ghrelin without Reducing Appetite in Adults with Prader-Willi Syndrome. Journal of Clinical Endocrinology and Metabolism, 2004, 89, 4162-4165.	1.8	113
54	Putting some spine into alternative splicing. Trends in Biotechnology, 2003, 21, 328-330.	4.9	7